APOLLO-BC APOLLO-BC: Advanced Perfused platform for Breast Cancer therapy-response prediction
- Coordinator
- Universidade Nova De Lisboa, Portugal
- Runs
- 1 October 2026 to 31 March 2028
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101334669
What the project is doing
In the project's own words, from its summary on CORDIS.
The limited ability of preclinical models to predict clinical responses remains a major barrier in oncology drug development. Current systems used for cancer drug evaluation, including conventional 2D cultures and advanced 3D models such as patient-derived organoids (PDOs), fail to control key tumour microenvironment (TME) parameters that influence drug penetration, adaptive resistance, and therapeutic response, potentially limiting predictive accuracy.
Consequently, a gap persists between preclinical efficacy and clinical response, highlighting the need for ex vivo systems with improved predictive performance. Breast cancer provides a clinically relevant setting to address this challenge. Subtypes such as TNBC and HER2-positive disease show substantial variability in response to approved therapies, creating a need for improved methods to prioritise treatment options.
APOLLO-BC tests whether controlling key tumour microenvironment parameters, specifically perfusion and mechanical stiffness, improves the predictive accuracy of therapy-response ranking compared with PDO systems. The project will generate the first controlled direct comparative validation of a perfused, stiffness-controlled tumour model against conventional PDO workflows using matched patient-derived samples. A microfluidic platform integrating bioprinted 3D tumour constructs and real-time environmental monitoring will be standardised, followed by generation of matched TNBC and HER2+ models and a benchmarking study across ≥40 patients, each tested with ≥6 approved therapeutic regimens.
Reproducibility and predictive concordance with retrospective clinical outcomes will be quantitatively compared with PDO workflows. By generating rigorous comparative evidence, APOLLO-BC will determine whether microenvironmental engineering improves predictive drug-response assessment in breast cancer models, establishing a validated framework for next-generation functional oncology platforms.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universidade Nova De Lisboa | Lisboa | Portugal | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI